Academic literature on the topic 'Atenolol'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Atenolol.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Atenolol"
1
Hurst, Agneta K., Avraham Shotan, Kristina Hoffman, et al. "Pharmacokinetic and Pharmacodynamic Evaluation of Atenolol during and after Pregnancy." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, no. 4 (1998): 840–46. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03906.x.
Full textAbstract:
Study Objective. To evaluate changes due to pregnancy on atenolol's pharmacokinetics, response of maternal heart rate to atenolol, and the drug's effect on fetal heart rate.Design. Prospective study.Setting. Large university teaching hospital.Patients. Fourteen pregnant women who were receiving oral atenolol for cardiac disease were enrolled and 10 completed the study.Interventions. Patients were studied for 12 hours during the third trimester (TT) and again 6 weeks postpartum (PP).Measurements and Main Results. Fetal heart rates, and maternal heart rates at rest and during exercise were recorded. Maternal plasma and urine atenolol concentrations were measured. Average resting heart rates (TT 68 ± 10, PP 62 ± 9 beats/min) and maximum heart rate during exercise (TT 100 ± 6, PP 87 ± 7 beats/min) were significantly higher in the third trimester than postpartum (p<0.05). The 12‐hour atenolol area under the curve (TT 0.208 ± 0.061, PP 0.215 ± 0.089 ng/ml/day) and maximum plasma concentrations during the time of exercise tests (TT 1.07 ± 0.39, PP 1.14 ± 0.53 mmol/L) were not significantly different. Individual and population pharmacokinetics did not differ significantly between study periods. The fetal heart rate did not correlate with maternal atenolol concentration.Conclusion. Constant dosages of atenolol result in higher heart rates during pregnancy compared with the postpartum period. This lack of heart rate control is not due to significant changes in atenolol's pharmacokinetics or plasma concentrations.
2
Celic, Vera, Biljana Pencic, Milica Dekleva, Sinisa Dimkovic, and Maksimilijan Kocijancic. "Metoprolol and atenolol in mild-to-moderate chronic heart failure: The comparison of survival benefit." Srpski arhiv za celokupno lekarstvo 133, no. 5-6 (2005): 242–47. http://dx.doi.org/10.2298/sarh0506242c.
Full textAbstract:
The clinical end-point of all causes of mortality and cardiovascular hospitalization (combined end-points) is a widely accepted indicator of heart failure survival. The primary aim of this study was to examine the effects of metoprolol and atenool on combined end-points in patients with mild-to-moderate heart failure. This study was designed to be comparative, prospective, and random. The criteria for study inclusion were: age of 70 years or less, New York Heart Association (NYHA) Functional Class II and III, and an ejection fraction of the left ventricle of 40% or less. The patients (a total of 150) on therapy with angiotensin-converting enzyme inhibitor and a diuretic were randomized into three numerically equal therapy groups: 1) an atenolol group; 2) a metoprolol group; and 3) a control group (without beta-blockers). The follow-up period was 12 months. The results were analyzed using: the hisquare test, variance analyses, Kaplan-Meier's model, Wilcox's statistics, and Cox's model. The cumulative survival rate for patients treated with metoprolol was 88%, 78% for patients treated with atenolol, and 48% for patients from the control group. It is clear that the cumulative survival rate for patients treated with metoprolol and atenolol is significantly higher compared to patients from the control group. In addition, the survival rate of patients treated with metoproiol was considerably higher compared to the survival rate of patients treated with atenolol. Metoprolol has significantly reduced the relative risk of combined end-points (71%) compared to atenolol (53%). The results of this comparative study clearly indicate that metoprolol and atenolol have a favorable effect on the survival rate of patients with chronic heart failure. In addition, metoprolol is considerably more effective than atenolol.
3
Keerthana G, Afroz Patan, Ramachandran S, Binoy Varghese Cheriyan, and Vijey Aanandhi M. "Comparative study of atenolol in human plasma by high performance liquid chromatography and capillary zone electrophoresis." International Journal of Research in Pharmaceutical Sciences 12, no. 2 (2021): 1422–27. http://dx.doi.org/10.26452/ijrps.v12i2.4709.
Full textAbstract:
Atenolol is a beta-blocker that is cardioselective, meaning it only affects beta receptors. It is used to treat angina pectoris and high blood pressure. The HPLC and Capillary Zone Electrophoresis analytical technique was developed for the purpose of detecting and quantifying Atenolol in human plasma, according to the study paper you're reading right now. The internal standard and atenolol were recovered from the solution after being extracted from plasma using the Liquid-Liquid Extraction method. A mobile phase of 10mM sodium hydrogen phosphate, 7.3mM Sodium Lauryl sulphate (pH=3), methanol, and acetonitrile (40:57:3, v:v:v) is used, with a flow rate of 1.0ml/min. A fluorescence detector was used to detect the isolated materials, which had an excitation wavelength of 229 nm and an emission wavelength of 298 nm. With this in view, Atenolol's and the internal norm's survival times are observed to be 5.4 and 8.3 minutes, respectively. The linear correlation coefficient (R20.9992) was found in the Atenolol calibration curve. The recovery rate for atenolol and an internal norm was estimated to be between 76 and 87 percent. Solid-phase extraction was performed on an uncoated silica capillary with a diameter of 58.5 cm 75 m, and detection was performed at 194 nm in the Capillary Zone Electrophoresis procedure. For an electrolyte solution containing 50mM H3BO3 and 50mM Na2B4O7 (50:50 V/V), atenolol was determined to be present in the solution in less than 3 minutes. Energized with a voltage of 25kV and injected with a hydrodynamic configuration for 4S. Under various conditions, this method was used to assess the stability and capability of measuring Atenolol in human plasma.
4
&NA;. "Atenolol see Diltiazem/atenolol." Reactions Weekly &NA;, no. 283 (1990): 4. http://dx.doi.org/10.2165/00128415-199002830-00007.
Full text
5
&NA;. "Atenolol see Propranolol/atenolol." Reactions Weekly &NA;, no. 339 (1991): 5. http://dx.doi.org/10.2165/00128415-199103390-00013.
Full text
6
Davé, Mahendra. "Treatment of Lithium Induced Tremor with Atenolol." Canadian Journal of Psychiatry 34, no. 2 (1989): 132–33. http://dx.doi.org/10.1177/070674378903400212.
Full textAbstract:
This is the first report on the successful treatment of one patient with lithium induced tremor with hydrophilic atenolol, which is a relatively selective beta 1 adrenergic receptor blocker. Atenolol's advantages over lipophilic beta blockers in the treatment of lithium induced tremor are discussed.
7
&NA;. "Atenolol." Reactions Weekly &NA;, no. 695 (1998): 6. http://dx.doi.org/10.2165/00128415-199806950-00016.
Full text
8
&NA;. "Atenolol." Reactions Weekly &NA;, no. 560 (1995): 7. http://dx.doi.org/10.2165/00128415-199505600-00018.
Full text
9
&NA;. "Atenolol." Inpharma Weekly &NA;, no. 1130 (1998): 19. http://dx.doi.org/10.2165/00128413-199811300-00042.
Full text
10
&NA;. "Atenolol." Reactions Weekly &NA;, no. 432 (1992): 6. http://dx.doi.org/10.2165/00128415-199204320-00023.
Full textDissertations / Theses on the topic "Atenolol"
1
Foppa, Talize. "Desenvolvimento e estudo de solução pediátrica contendo atenolol." Florianópolis, SC, 2006. http://repositorio.ufsc.br/xmlui/handle/123456789/88459.
Full textAbstract:
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Farmácia.<br>Made available in DSpace on 2012-10-22T09:17:35Z (GMT). No. of bitstreams: 0<br>Hipertensão é a doença cardiovascular com maior prevalência no mundo. Existe ampla evidência que tenha início na infância. A seleção da terapia apropriada depende da causa da doença e da idade da criança. Muitos fatores afetam a escolha de um anti-hipertensivo quando da otimização do tratamento em crianças. Entre eles estão o diagnóstico, a severidade da doença, as complicações, as doenças paralelas, a utilização de outros fármacos e a formulação do medicamento. O manejo da hipertensão em crianças inclui o uso de bloqueadores, inibidores da enzima conversora da angiotensina, bloqueadores de canais de cálcio e diuréticos. A maioria dos fármacos prescritos para crianças não possui forma farmacêutica apropriada pra este fim. A falta extensiva de dados sobre o uso dos antihipertensivos pediátricos aponta para estudos que incluem somente fármacos com algum potencial perigoso descrito na literatura. O atenolol é um fármaco pertencente à classe dos ß bloqueadores. Esta classe de fármacos vem sendo utilizada na pediatria, mesmo estando disponível no mercado somente em apresentações para adultos. O objetivo deste trabalho foi desenvolver e avaliar uma formulação de atenolol em veículo xarope destinado à utilização em ambiente hospitalar. Realizou-se a caracterização da matéria prima. Foi desenvolvida formulação líquida de atenolol utilizando o xarope como veículo. Realizou-se o controle de qualidade da água, seguido das análises físico-químicas e microbiológicas do xarope contendo o fármaco. Estudo da estabilidade do atenolol frente ao calor foi desenvolvido. Padronizou-se o método para doseamento do fármaco em plasma de ratos, assim como a avaliação da eficácia nos animais pela diminuição da freqüência cardíaca. Realizou-se estudo clínico em pacientes internados no Hospital Infantil Joana de Gusmão, com a avaliação da evolução do quadro clínico das crianças. Os resultados farmacocinéticos obtidos experimentalmente em ratos mostraram diferenças significativas do fármaco em veículos distintos, e a inclusão deste medicamento na rotina do Hospital Infantil Joana de Gusmão resultou na melhora dos parâmetros clínicos e controle da sintomatologia das patologias apresentadas pelos pacientes.
Hipertension is the cardiovascular illness with most prevalence in the world. Ample evidence exists that has beginning in infancy. The election of the appropriate therapy depends on the cause of the illness and child'age. Many factors affect the choice of an antihypertensive when of the otimization of the treatment in children. Between them they are the diagnosis, the severity, the complications, the illnesses parallel and the use of other drugs. The hipertension treatment in children includes the use of ß blockers, inhibitors of the converting enzyme of the angiotensine, blockers of calcium canals and diuretcs. The majority of the drugs prescribed for children are not available in suitable dosage forms. The extensive lack of data on the use of pediatrics antihypertensives points with respect to studies that only include drugs with some described dangerous potential in literature. Atenolol is a pertaining drug to the class of ß blokckers. This drugs comes being used in the pediatrics, exactly being available in the market only in presentations for adults. The objective of this work was to develop and to evaluate a formularization of atenolol in syrup must destined to the use in hospital environment. It was analysed the characterization of the raw material. Atenolol liquid was developed using the syrup vehicle. The quality control of the water was developed, followed of the analyses microbiological, chemistries and of the syrup contend the drug. Study of the stability of atenolol front to the temperature. Analytical methodology for assay of the drug in mouse's plasma was standardized, as well as the evaluation of the effectiveness in the animals for the reduction of the cardiac frequency. Clinical study in patients interned in the Hospital Joana de Gusmão was studied with the evolution of the clinical of the children. The pharmacokinetics results in rats had experimentally shown significant differences of the same drug with distinct vehicles and the inclusion of this medicine in the Hospital Joana de Gusmão routine in such a way showed improvement of the patients in the clinical parameters, as in the sintomatology of the presented patology.
2
Waterman, Mari. "Pharmacodynamic evaluation of beta-blockade associated with atenolol in healthy dogs." Thesis, Virginia Tech, 2018. http://hdl.handle.net/10919/97339.
Full textAbstract:
Objective: Dosing intervals of 12 and 24 hours for atenolol have been recommended, but an evidentiary basis is lacking. To test the hypothesis that repeated, once-daily oral administration of atenolol attenuates the heart rate response to isoproterenol for 24 hours, we performed a double-blind, randomized, placebo-controlled cross-over experiment.
Animals: Twenty healthy dogs
Procedures: Dogs were randomly assigned to receive either placebo (P) and then atenolol (A), [1 mg/kg PO q24h] or vice versa. Treatment periods were 5-7 days; time between periods was 7 days. Heart rates (bpm) at rest (HRr) and during constant rate [0.2 μg/kg/min] infusion of isoproterenol (HRi) were electrocardiographically obtained 0, 0.25, 3, 6, 12, 18, and 24 hours after final administration of drug or placebo. A mixed model ANOVA was used to evaluate the effects of treatment (Tr), time after drug or placebo administration (t), interaction of treatment and time (Tr*t) as well as period and sequence on HRr and HRi.
Results: Sequence or period effects were not detected. There was a significant effect of Tr (p <0.0001) and Tr*t (p <0.0001) on HRi. Atenolol significantly attenuated HRi for 24 hours but did so maximally at 3 hours (least squares means ± SE, A: 146±5 bpm, P: 208±5 bpm); the effect at 24 hours was small (A: 193±5, P: 206±5). Atenolol had a small but significant effect (p <0.0001) on HRr.
Conclusions and Clinical Relevance: The results of this study support a dosing interval that is less than 24 hours.<br>MS
3
Newkirk, Alicia. "A Comparison of Content and Quality of Atenolol and Captopril Manufactured in Mexico and the United States." The University of Arizona, 2005. http://hdl.handle.net/10150/624764.
Full textAbstract:
Class of 2005 Abstract<br>Objectives: To determine whether the quantity of active ingredient and content uniformity of atenolol and captopril manufactured in Mexico are comparable with those manufactured in the United States.
Methods: An adapted United States Pharmacopoeia-National Formulary (USP-NF) guideline was utilized for a high-performance liquid chromatography (HPLC) assay to quantify the active ingredient of each medication. The US products were considered to contain 100% of the active ingredient, with acceptable variance range of 90-110%. Atenolol 50 milligrams (mg) and captopril 50 mg tablets, manufactured from either Mexico or US, were tested in this comparative study.
Results: Quantification of active ingredient in Mexican captopril 50 mg tablets were within the acceptable range of the USP-NF guidelines at 94.2%. The content uniformity was also within the acceptable range of the USP-NF guidelines at 99.0%. The quantity of active ingredient in the Mexican atenolol 50 mg tablets, as well as content uniformity, was also within the acceptable range of the USP-NF guidelines at 110.0% and 95.0%, respectively.
Implications: The results of this study showed that captopril and atenolol manufactured in Mexico were comparable to those manufactured in the US with no significant differences regarding amount of active ingredient and content uniformity.
4
Blazy, Pierre. "Evaluation quantitative de la cardioprotection par un betabloquant (atenolol) lors de l'angioplastie transluminale endocoronaire." Toulouse 3, 1991. http://www.theses.fr/1991TOU31021.
Full text
5
Gil, Ana Cecilia Montes. "Avaliação farmacologica do aspirinato de atenolol como droga antiplaquetaria e anti-hipertensiva." [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/309492.
Full textAbstract:
Orientador: Gilberto de Nucci<br>Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas<br>Made available in DSpace on 2018-08-11T00:01:00Z (GMT). No. of bitstreams: 1
Gil_AnaCeciliaMontes_D.pdf: 1050627 bytes, checksum: 72f41a4bdcddba6633b8b082cc0ee0a0 (MD5)
Previous issue date: 2007<br>Resumo: No presente trabalho, foram avaliados os efeitos farmacológicos do Aspirinato de atenolol (AA T) uma potencial pró-droga mútua resultado da combinação química entre ácido acetilsalicílico (AAS) e atenolo!. As propriedades do AA T como droga antitrombótica foram avaliadas na inibição da agregação plaquetária estimulada in vitro e na inibição da produção de tromboxano estimulada ex-vivo em sangue de animais tratados. Por outro lado, o AA T foi avaliado como droga anti-hipertensiva no modelo de hipertensão induzida pela inibição crônica da síntese de NO em ratos, e seus efeitos como antagonista dos adrenoceptores 13 foram avaliados na resposta cronotrópica ao isoproterenol em átrios isolados. Foi determinada a estabilidade metabólica em diferentes frações subcelulares hepáticas, plasma e soluções tampão de diferente pH, assim como seu perfil farmacocinético após administração endovenosa. Também foram avaliadas as propriedades ulcerogênicas gástricas e o potencial mutag'ênico através do Teste de Ames. Os resultados mostraram na avaliação do efeito antiplaquetário, que o AA T não inibiu a agregação plaquetária induzida pelo ácido araquidônico em nenhuma das concentrações testadas e apesar d~ ini~ir significativamente a produção de tromboxano estimulada ex-vivo em rat6s e na maior dose testada em camundongos, este efeito inibitório foi menor quando comparado com o AAS. O acoplamento com AAS, na molécula de AAT, suprimiu os efeitos do atenolol como antagonista dos adrenoceptores 13. Igualmente, o AA T não reduziu a freqüência cardíaca e pressão arterial após tratamento oral crônico de ratos hipertensos, estes resultados indicaram que não houve liberação de atenolol desde a molécula de AA T. Na avaliação da estabilidade metabólica e farmacocinética, observamos que o AA T seguiu uma rápida e completa hidrólise no grupo orto-acetila, gerando salicilato de atenolol (SA T), este produto foi formado quando o AA T foi submetido à hidrólise plasmática (T% 7,6 min) e aquosa (T% 56,5; 24,9 e 6,4 nos pH 2,5; 7,4 e 9.4 respectivamente) metabolização hepática e também após administração endovenosa em cães. o salicilato de atenolol formado a partir do AA T nas frações subcelulares hepáticas foi metabolizado apenas na fração microssomal gerando dois metabólitos hidroxilados em posições diferentes na molécula, a formação destes metabólitos foi dependente do tempo e paralela à cinética de desaparecimento do SAT. Após administração endovenosa, concentrações de AA T não foram detectadas em plasma. Atenolol e ácido salicílico (AS), foram liberados a partir da molécula de SAT (após clivagem da ligação éster benzoato) em concentrações significativamente menores às concentrações obtidas nos grupos tratados com AAS ou atenoloL A ASC0-24h calculada para o AS no grupo tratado com AA T correspondeu ao 0,71% da área calculada para o grupo que recebeu AAS. Similarmente, a ASC0-24h do atenolol no grupo tratado com AA T correspondeu a 1,44% da área calculada para ~ grupo tratado com atenolol. O AA T e seu principal metabólito SA T, não apresentaram propriedades mutagênicas, obtendo-se resultados negativos no Teste de Ames. O AA T produziu lesões na mucosa gástrica significativamente menores às observadas com o AAS após administração oral aguda e crônica durante 4 semanas. Devido às relevantes diferenças obtidas entre o AA T, AAS ou atenolol na caracterização farmacológica e farmacocinética, concluímos que o AA T não atua como pró-droga mútua de AAS e atenolol, e modificações futuras na molécula devem ser consideradas com a finalidade de desenvolver aspirinatos cardioativos com potencial efeito farmacológico<br>: In this study, we evaluated the pharmacologica/ effects of Atenolol Aspirinate (A TA) a potential mutual prodrug that resulted of the chemical combination between Acetyl Salicylic Acid (ASA) and atenolo!. The properties of ATA as anthithrombotic drug were evaluated on the inhibition of in vitro stimulated platelet aggregation and on the inhibiton of ex-vivo stimulated thromboxane production in blood from treated animais. Additionally, A TA was evaluated as an antihypertensive drug on the hypertension induced by chronic inhibition of NO in rats, its effects as antagonist of f3 adrenoceptors were evaluated in the chronotropic response to isoproterenol in isolated atria. The metabolic stability was determined in different hepatic subcellular fractions, plasma and buffer solutions as well as its pharmacokinetic profile after intravenous administration. The gastric ulcerogenic properties and mutagenic potencial, using the Ames test, were toa evaluated. In the evaluation of the antiplatelet effect, our results showed that ATA had no effect on arachidonic acid induced platelet aggregation. Although it inhibited significantly the ex-vivo stimulated thromboxane production in rats and in the highest tested dose in mice, ATA showed lower inhibitory effect than ASA. The coupling with ASA, in the ATA mOlecule, abolished the atenolol effects as antagonist of f3 adrenoceptors. In the sa~e"way, ATA had no effect reducing the heart rate and blood pressure after chropic oral treatment of hypertensive rats, these results showed that atenolol was not liberated from ATA molecule. In the evaluation of the metabolic stability and pharmacokinetics, we observed that ATA followed a rapid and complete hydrolysis at the o-acetyl group, generating atenolol salicylate (A T8), this product was formed when ATA was submitted to plasma hydro/ysis (T% 7;6 min) and aqueous hydrolysis (T% 56,5; 24,9 and 6,4 at pH 2,5; 7,4 and 9.4 respectively), hepatic metabolization and after intravenous administration to dogs. ATA was biotransformed to A TS in ali hepatic subcellular fractions, then A TS was metabolized only in the microsomal fraction generating two hydroxylated metabolites, whose formation was time dependent and parallel to the kinetics of A TS consumption. After intravenous administration, concentrations of A TS instead ATA were found in plasma dog samples, SA and atenolol were originated from cleavage of A TS molecule at the benzoate ester linkage, generating concentration levels to a lesser extent than levels found after treatment with an equimolar dose of the drugs ',nóiviõua<br>Doutorado<br>Doutor em Farmacologia
6
Haro, Nathalia Krummenauer. "Remoção dos fármacos atenolol, paracetamol e ampicilina por adsorção em carvão ativado." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2017. http://hdl.handle.net/10183/172254.
Full textAbstract:
Os fármacos são essenciais para a preservação da saúde do homem e de animais e também na prevenção de doenças. Entretanto, seu alto consumo associado ao descarte incorreto e aos tratamentos ineficientes de águas e efluentes podem trazer grandes prejuízos ao meio ambiente como, por exemplo, a resistência bacteriana. O objetivo deste trabalho foi estudar a remoção de ampicilina (AMP), atenolol (ATN) e paracetamol (PAR), fármacos de três classes distintas, em soluções aquosas através da técnica de adsorção em carvão ativado granular (CAG). Foram realizados experimentos de adsorção em batelada avaliando o efeito dos parâmetros pH, tempo de contato e concentração de sólido adsorvente. O comportamento cinético da adsorção dos fármacos em carvão ativado granular foi avaliado por meio dos modelos de pseudo-primeira ordem, pseudosegunda ordem e difusão intrapartícula. Ainda, isotermas de equilíbrio para estes sistemas foram construídas em diferentes temperaturas (15, 25 e 35 °C) e analisadas através dos modelos de Langmuir, Freundlich e Sips. O processo de adsorção também foi avaliado através de ensaios termodinâmicos. A adsorção em coluna de leito fixo foi avaliada utilizando planejamentos experimentais para os fármacos e os efeitos da massa do leito de adsorvente (0,5 – 1,5 g) e da vazão de alimentação (10 – 15 mL min-1) foram estudados Ainda, a fim de se avaliar o comportamento dos fármacos quando em mistura, foram realizados ensaios de adsorção em batelada e em coluna de leito fixo da mistura de ampicilina e paracetamol. Os melhores resultados encontrados nos ensaios de adsorção batelada foram: pH 6 e concentração de sólido adsorvente de 10 g L-1 para os três fármacos. O tempo de adsorção mais adequado foi de 90 minutos para o ATN e 120 min para AMP e PAR. Nessas condições foi possível obter remoções de 90 %, 94 % e 96 % para a ampicilina, atenolol e paracetamol, respectivamente. O modelo cinético que melhor descreveu o processo de adsorção foi o de pseudo-primeira ordem, para os fármacos ampicilina e paracetamol, e pseudo-segunda ordem para o atenolol. As isotermas obtidas para os fármacos indicaram que o processo de adsorção é de natureza endotérmica, ou seja, a adsorção é favorecida com o aumento da temperatura. Para a AMP, o melhor ajuste das isotermas foi obtido pelo modelo de Langmuir nas temperaturas de 15 ºC e 25 ºC e pelo modelo de Sips na temperatura de 35 ºC. Para o ATN, o melhor ajuste foi obtido pelo modelo de Freundlich e, para o PAR, o modelo de Sips, nas três temperaturas estudadas. Os ensaios termodinâmicos indicaram que o processo de adsorção dos fármacos é favorável e espontâneo e comprovou a natureza endotérmica do processo Em relação aos resultados obtidos na adsorção em coluna de leito fixo foi observado que os tempos de ruptura e de saturação aumentam com o aumento da massa de sólido presente no leito e diminuem com o aumento da vazão. A massa de adsorvente apresentou efeito negativo sobre a fração de leito utilizado e foi significativa no processo de adsorção dos três fármacos. Já a vazão de alimentação só foi significativa na adsorção em leito fixo da AMP e apresentou efeito positivo na fração de leito utilizado. Os maiores volumes de efluente tratado foram obtidos com a maior massa de sólido utilizada (1,5 g) e com a menor vazão de alimentação testada (10 mL min-1). Na adsorção multicomponente em batelada, verificou-se que há concorrência entre os fármacos pelos sítios ativos do CAG disponíveis para adsorção. Os resultados obtidos nos ensaios das isotermas de adsorção mostraram que o comportamento dos fármacos em mistura é o mesmo que quando comparados individualmente. Os modelos que melhor se ajustaram aos dados experimentais foram os mesmos obtidos nos ensaios monocomponente, Langmuir para a AMP e Sips para o PAR. Da mesma forma que para os experimentos em coluna monocomponente, os ensaios multicomponentes demostraram que os tempos de ruptura e de saturação são maiores para o PAR. Entretanto, esses valores são menores do que na adsorção individual indicando que houve concorrência entre os fármacos pelos sítios do adsorvente. Os resultados encontrados indicam que a adsorção é uma alternativa viável para a remoção de fármacos, contribuindo, assim, para o avanço das pesquisas relacionadas ao tratamento de efluentes contaminados por estes poluentes.<br>Drugs are essential for preservation of human and animal health as well as for disease prevention. However, its high consumption associated with incorrect disposal and inefficient treatment of water and effluents can cause great damage to the environment such as bacterial resistance, for example. The objective of this work was to study the removal of ampicillin (AMP), atenolol (ATN) and paracetamol (PAR), drugs of three different classes, in aqueous solutions by adsorption technique in granular activated carbon (GAC). Adsorption experiments were carried out in batch evaluating the effect of parameters pH, contact time and concentration of solid adsorbent. The kinetic behavior of the adsorption of drugs in granular activated carbon was evaluated through the pseudofirst order, pseudo-second order and intraparticle diffusion models. Furthermore, equilibrium isotherms for these systems were made at different temperatures (15, 25 and 35 ° C) and analyzed using the Langmuir, Freundlich and Sips models. The adsorption process was also evaluated through thermodynamic tests. The fixed bed column adsorption was evaluated by experimental planning for drugs and the effects of mass of the adsorbent bed (0.5 to 1.5 g) and feed rate (10 - 15 ml min-1) were studied Also, in order to evaluate the behavior of the drugs when in mixture, adsorption tests were carried out in batch and in fixed bed column for the mixture of ampicillin and paracetamol. The best results found in the batch adsorption tests were: pH 6 and concentration of adsorbent solid of 10 g L-1 for the three drugs. The most suitable adsorption time was 90 minutes for ATN and 120 min for AMP and PAR. Under these conditions it was possible to obtain removals of 90%, 94% and 96% for ampicillin, atenolol and paracetamol respectively. The kinetic model that best described the adsorption process was the pseudo-first order for the ampicillin and paracetamol drugs and pseudo-second order for atenolol. The isotherms obtained for the drugs indicated that the adsorption process is of endothermic nature, that is, the adsorption is favored with the increase in temperature. For the AMP, the best isotherm adjustment was obtained by the Langmuir model at temperatures of 15 °C and 25 °C and by the Sips model at temperature of 35 °C. For the ATN, the best fit was obtained by the Freundlich model and, for PAR, the Sips model at the three temperatures studied. The thermodynamic tests indicated that the adsorption process of the drugs was favorable and spontaneous and confirmed the endothermic nature of the process Regarding the results obtained in adsorption in fixed bed column, it was observed that rupture and saturation times increase with the increase of the mass of solid present in the bed and decrease with the increase of flow. The adsorbent mass had a negative effect on the used bed fraction and was significant in the adsorption process of the three drugs. The feed flow was only significant in the adsorption in fixed bed of the AMP and had positive effect in the used bed fraction. The highest volumes of treated effluent were obtained with the largest mass of solid used (1,5 g) and with the lowest feed rate tested (10 mL min-1). In multicomponent adsorption in batch, it was found that there is competition between the drugs by the active sites of GAC available for adsorption. The results obtained in the adsorption isotherms tests showed that the behavior of the drugs in mixture is the same as when compared individually. The models that best fit the experimental data were the same ones obtained in the monocomponent tests, Langmuir for AMP and Sips for PAR. Similarly as for the monocomponent column experiments, the multicomponent tests showed that the break and saturation times are larger for the PAR. However, these values are lower than in individual adsorption indicating that there was competition between the drugs for the sites of the adsorbent. The results indicate that adsorption is a viable alternative for the removal of drugs, thus contributing to the advancement of research related to the treatment of effluents contaminated by these pollutants.
7
Leite, Fátima da Silva. "Avaliação da disposição cinética do atenolol em pacientes coronarianos submetidos à revascularização do miocárdio. Influência da circulação extracorpórea sobre as concentrações plasmáticas do atenolol no intra-operatório de cirurgia cardíaca." Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/9/9141/tde-08022009-174706/.
Full textAbstract:
Pacientes submetidos à revascularização do miocárdio (RM), frequentemente utilizam beta-bloqueadores no pré-operatório para o controle da angina pectoris, e continuam o tratamento após a cirurgia, para a redução de mortalidade e complicações cardiovasculares perioperatórias. Entretanto, a circulação extracorpórea (CEC), empregada na maioria das cirurgias cardíacas, pode alterar as concentrações plasmáticas e a disposição cinética de muitos fármacos, e consequentemente seus efeitos terapêuticos. O atenolol é um beta-bloqueador altamente hidrossolúvel, de absorção incompleta e eliminação renal-dependente. O objetivo deste estudo foi o de investigar a influência da CEC sobre as concentrações plasmáticas do atenolol no intra-operatório de cirurgia cardíaca, além de comparar a sua farmacocinética no pré e pós-operatório de RM com CEC, em pacientes com insuficiência coronariana. Investigou-se ainda, a variabilidade das concentrações plasmáticas do atenolol no período que antecede a cirurgia cardíaca. Na primeira etapa, avaliaram-se 19 pacientes coronarianos, em terapia crônica com atenolol PO, submetidos à cirurgia cardíaca com ou sem CEC. Na segunda parte, investigaram-se os períodos pré e pós-cirúrgico de 7 pacientes submetidos à RM com CEC e tratados com atenolol PO em regime de doses múltiplas. Todos os pacientes investigados apresentavam função renal dentro da normalidade ou leve disfunção renal, decorrente da idade e da insuficiência coronariana. O monitoramento do atenolol plasmático no intra-operatório de RM e o estudo farmacocinético realizado antes e após a revascularização, exigiram coletas de amostras sangüíneas seriadas. A quantificação do atenolol em plasma foi realizada através da cromatografia líquida de alta eficiência com detector de fluorescência e consistiu num procedimento analítico rápido, simples e de baixo custo. Apenas 200 L de plasma foram utilizados em cada análise cromatográfica. O estudo de validação demonstrou que o método desenvolvido apresenta alta linearidade, sensibilidade e seletividade adequadas, alta recuperação, boa precisão e exatidão, além de estabilidade e robustez. Conclui-se que a circulação extracorpórea altera as concentrações do atenolol no intra-operatório de RM, visto que o decaimento das concentrações plasmáticas mostrou-se mais pronunciado na ausência da CEC. Entretanto, apesar das maiores concentrações obtidas ao final da cirurgia com CEC, o atenolol mostra-se seguro, em virtude do baixo acúmulo do fármaco administrado em regime de doses múltiplas. Além disso, a disposição cinética do atenolol permaneceu inalterada, quando os períodos pré e pós-operatórios foram comparados; entretanto, registrou-se uma tendência à normalização do volume de distribuição e da depuração plasmática do atenolol após a revascularização. Adicionalmente, a ausência de correlação entre meia-vida biológica e volume aparente de distribuição sugere que, tanto no pré quanto no pós-operatório, as concentrações do atenolol dependem apenas da sua depuração plasmática. Finalmente, verificou-se que o atenolol apresenta baixa variabilidade inter-pacientes nos regimes posológicos empregados no tratamento da insuficiência coronariana.<br>Patients submitted to coronary artery bypass grafting (CABG) surgery frequently are using beta-blockers agents for the control of angina pectoris, and continue the treatment after the surgery to reduce the mortality and cardiovascular events. However, the technique of cardiopulmonary bypass (CPB), used in most cardiac surgeries with cardioplegia, causes important changes in the plasma concentrations and pharmacokinetics of many drugs and may also alter their therapeutic effects. Atenolol is a hydrophilic beta-blocker characterized by incomplete absorption, a relatively small volume of distribution and a renal function-dependent elimination. The objective of this study was to investigate the effects of CPB on the plasma concentrations of atenolol during the intra-operative period of cardiac surgery, as well as, to compare the pharmacokinetics of atenolol in the pre and post-operative periods of revascularization with CPB, in patients with coronary insufficiency. In addition, it was investigated the variability of plasma atenolol concentrations before the cardiac surgery. In the first part of the study, it was investigated 19 coronary patients, under chronic therapy with atenolol and submitted to cardiac surgery performed with and without CPB. At the second part, it was evaluated the pre and post-operative periods from 7 patients submitted to the CABG surgery with CPB, who were chronically treated with atenolol in a multiple regimen. All enrolled patients presented normal or slightly reduced renal function as a result of age and underlying disease. A serial blood samples collection was required for monitoring of plasma atenolol concentrations at the intra-operative period and also for pharmacokinetic study at the pre and post-CABG. The quantification of plasma atenolol was performed using high-performance liquid chromatography with fluorescence detection and consisted of a relatively rapid, simple and low-cost analytical procedure. Only 200 µL of plasma was used for each chromatographic analysis. Validation of this analytical method showed high linearity, adequate sensitivity and selectivity, high recovery, good accuracy and precision, in addition to stability and a guarantee of robustness. It was concluded that the CPB changes plasma atenolol concentrations in the intra-operative period, since a marked decrease in plasma atenolol concentrations was observed in patients undergoing cardiac surgery without CPB. Thus, despite the lower decline in plasma levels observed in patients submitted to CPB, atenolol can be used safely, due to the low accumulation of the drug administrated at multiple dose regimens. In addition, pharmacokinetics of atenolol remained unaltered when pre and post-operative periods were compared; although it was observed a tendency of normalization of volume of distribution and plasma clearance of atenolol after the revascularization. Moreover, the lack of correlation between biological half-life and apparent volume of distribution suggests that, in both periods, plasma atenolol concentration only depends on its plasma clearance. Finally, it was verified a small inter-patient variability of atenolol in the dose regimens used for the control of coronary insufficiency.
8
Prado, Anelise Weich do. "OTIMIZAÇÃO DA AVALIAÇÃO DA MATÉRIA PRIMA E COMPRIMIDOS DE ATENOLOL: APLICAÇÃO EM PRODUÇÃO, CONTROLE E REGISTRO DE MEDICAMENTO GENÉRICO." Universidade Federal de Santa Maria, 2007. http://repositorio.ufsm.br/handle/1/5992.
Full textAbstract:
The atenolol is a selective β-blocker that acts specially on β-one adrenergic receptors of the heart, used in the control of high blood pressure, pectoris angine, cardiac arrhythmias and the treatment of miocardic stroke. This paper aimed to optimize the described methodologies for drugs and tablets of atenolol. It proposes to develop and validate simple and more accessible tests to evaluate atenolol tablets and raw material. It also emphasizes the ideal characteristics for drugs in the pre-formulation and development of the pharmaceutical form. Methodologies were developed and validated by HPLC and UV spectrophotometric for the quantification of atenolol in tablets. Raw material characterization techniques were also applied for the classification of atenolol in the pre-formulation. A pharmaceutical equivalence test was performed and compared to the national market reference drug. The HPLC developed method presents advantages over the official methodology to establish an analysis without the use of
ionic pareator heptane sulphonate, for being faster and more simple. Both quantitative development methods were linear, specific exact, precise, robust and equivalent between
themselves. For the dissolution performed with atenolol pharmaceutical form, after the dissolution efficiency analysis no meaningful difference were observed between the obtained
dissolution curves through developed methods and the pharmacopeial methodology. The atenolol raw material analysis permitted its characterization, assuring an adequate use in the pharmaceutical form manufacturing. The comparative analysis between the test drug and reference drug allowed to claim that the two formulations are similar and with the some in vitro performance, i.c., they are pharmaceutical equivalent. The described methods are useful
in routine quality analysis control of atenolol. The comparative analysis between the proposed methods and official methodology demonstrated that there is no statistical meaningful differences characterizing their equivalence.<br>O atenolol é um betabloqueador seletivo que age preferencialmente sobre os receptores adrenérgicos beta-1 do coração, utilizado no controle da hipertensão arterial, angina pectoris, arritmias cardíacas e no tratamento do infarto do miocárdio. Este trabalho tem o objetivo de otimizar as metodologias descritas para a avaliação do fármaco e comprimidos de atenolol, através do desenvolvimento e validação de métodos simples e mais acessíveis para avaliação
de comprimidos e matéria prima de atenolol. Procura, também, destacar as características ideais para o fármaco na fase de pré-formulação e desenvolvimento da forma farmacêutica.
Neste contexto, foram desenvolvidas e validadas metodologias por cromatografia líquida de alta eficiência (CLAE) e espectrofotometria no ultravioleta para quantificação de atenolol em comprimidos. Foram também aplicadas técnicas de caracterização da matéria prima para
classificação da mesma na fase de pré-formulação. O método desenvolvido por cromatografia líquida de alta eficiência apresenta vantagens sobre o método farmacopeico por estabelecer uma análise sem utilização de reagente de pareamento iônico, heptanossulfonato, por ser mais rápido e simples. Ambos os métodos quantitativos desenvolvidos apresentaram-se lineares, específicos, exatos, precisos, robustos, e equivalentes entre si. Para o estudo de dissolução
realizado com as formulações farmacêuticas de atenolol, após a análise de eficiência de dissolução, não se observou variação significativa entre as curvas de dissolução obtidas
através dos métodos desenvolvidos e da metodologia farmacopeica. A análise da matériaprima de atenolol permitiu sua caracterização, garantindo um emprego adequado na
fabricação da forma farmacêutica. As análises comparativas entre o medicamento teste e o medicamento referência permitem afirmar que as duas formulações são semelhantes e com mesmo desempenho in vitro, isto é, são equivalentes farmacêuticos. Os métodos descritos são úteis em análise de controle de qualidade rotineira de formulações farmacêuticas de atenolol e a análise comparativa entre os métodos propostos e a metodologia oficial, demonstrou não haver diferença estatisticamente significativa, caracterizando a equivalência dos mesmos.
9
Martins, Maria Lucia. "Estudo de bioequivalencia de duas formulações de comprimidos de atenolol em voluntarios sadios." [s.n.], 1997. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310680.
Full textAbstract:
Orientador: Marcelo Nicolas Muscara<br>Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas<br>Made available in DSpace on 2018-07-22T13:03:56Z (GMT). No. of bitstreams: 1
Martins_MariaLucia_M.pdf: 1996921 bytes, checksum: 89b8a8047b16cfbfaa60acc0642b10d5 (MD5)
Previous issue date: 1997<br>Resumo: Neste trabalho foram comparadas as biodisponibilidades de duas formulações de comprimidos de atcnolol: Atcnol, comprimidos 50 mg, (Laboratório Wellcomc ICI; formulação de referência) versus Angipress, comprimidos 50 mg (Laboratório Biosintética; formulação teste), em dezoito voluntários sadios do sexo masculino. O protocolo clínico constava de dois períodos randômicos, com intervalo de quatorze dias entre as doses, aprovado pelo comitê de ética do Hospital de Clínicas da UNICAMP. Os voluntários, após uma triagem, foram hospitalizados às 23 horas ao dia anterior do estudo clínico sob jejum e, às 7 horas do dia seguinte, iniciou-se o ensaio clínico. Os voluntários receberam uma única dose de atenolol de cada formulação. As amostras de sangue foram obtidas imediatamente antes e a intervalos regulares, até 24 horas após a administração da droga. A concentração plasmática de atenolol foi determinada por HPLC com detecção fluorin1étrica. Os parâmetros farmacocinéticos obtidos de cada formulação de atenolol foram: área sobre a curva da concentração plasmática em função do tempo de O até 24 h (AUC[O-24), concentração máxima alcançada (Cmax) e o tempo empregado para ser a1cançada (tmax), meia vida de eliminação {tll2), constante de eliminação terminal de primeira ordem (ke) e a área sobre a curva extrapolada ao infInito (AUC[o-oo).Todos os parâmetros farmacocinéticos foram analisados por métodos estatísticos paramétricos e não-paramétricos. As duas formulações de comprimidos de atenolol não apresentaram diferenças estatísticamente significantes em biodisponibilidade. Com base nos resultados obtidos e de acordo com os requerimentos estipulados pela EU e a FDA (EUA) as duas formulações foram consideradas bioequivalentes, com referência tanto à velocidade quanto ao grau de absorção<br>Abstract: The bioavailability of two atcnolol tablct rormulations: Angipress (rrom Laboratórios Biosintética, SP, Brazil), and Atenol (fram Wellcome ICI Laboratory, SP, Brazil) were compared in eighteen healthy male volunteers who received a single dose of 50 I mg 01' cach [ormulation, in. an open randomizcd two pcriod crossover fashion with a fourteen day washout interval between doses. Plasma samples were obtained over a 24 h interval and atenolol concentrations were determined by HPLC with tluorimetric detection. From thc plasma atenolol conccntration vs time curves, AUqO.24) (area under the concentration vs time curves fram O to 24 h), Cnax (maximum achieved concentration), tmax (time to achieve Cnax), ty, (terminal fIrst arder c1imination half-life), ke (terminal fIrst arder eliminati?n constant) and AUC (arca under thc' concentration vs time curves extrapolated to I infinity) wcre obtained. All thesc variables wcre analysed using both parametric and non parametric statistics. The two atenolol tablct bránds did not show statistically signwcant dilTerences in bioavailability as assessed by analyses 01' AUC[O.24), AUC, Cmax, trnax, t'h, and kc valucs. Bascd on thcse results and on thc Unitcd Statcs Food and Drug Administqllion (FDA) and the European Union requerimcnts, we conc1udc that both formulations are bioequivalent<br>Mestrado<br>Farmacologia<br>Mestre em Ciências
10
Elias, Gracieli Prado [UNESP]. "Efeito da hipertensão e do atenolol sobre a atividade salivar e a microdureza dental: estudo experimental em filhotes de ratas espontaneamente hipertensas (SHR)." Universidade Estadual Paulista (UNESP), 2006. http://hdl.handle.net/11449/104235.
Full textAbstract:
Made available in DSpace on 2014-06-11T19:33:01Z (GMT). No. of bitstreams: 0
Previous issue date: 2006-12-15Bitstream added on 2014-06-13T19:03:54Z : No. of bitstreams: 1
elias_gp_dr_araca.pdf: 1560641 bytes, checksum: 3dad8c2298005cfeb8d0a078880f5e66 (MD5)<br>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)<br>O objetivo deste trabalho foi avaliar a atividade das glândulas salivares, a mineralização dental e a participação da metaloproteinase de matriz (MMP-9) nesta mineralização em filhotes de ratas espontaneamente hipertensas (SHR) tratadas ou não com atenolol. Ratas SHR e normotensas Wistar foram tratadas com atenolol (100mg/Kg/dia, via oral) durante os períodos de prenhez e lactação. Os grupos controle receberam o mesmo volume de água sem atenolol. O fluxo salivar, induzido por nitrato de pilocarpina, a concentração de proteínas (método de Lowry), a atividade da amilase (método cinético a 405 nm), o peso das glândulas salivares (parótidas, submandibulares e sublinguais), a microdureza do esmalte e da dentina de incisivos e molares e a expressão da MMP-9 (imonuperoxidase) no tecido dental foram comparados entre filhotes de ratas SHR e Wistar tratadas ou não com atenolol. Os resultados obtidos foram submetidos ao teste estatístico mais adequado, paramétrico (ANOVA ou test t de Student’s) ou não paramétrico (Kruskal-Wallis), sendo consideradas significativas as diferenças quando p<0,05. Filhotes SHR apresentaram menor fluxo salivar e concentração de proteínas do que filhotes Wistar, mas a atividade da amilase não foi diferente entre os grupos. O peso das glândulas salivares foi semelhante entre filhotes SHR e Wistar...<br>The objective of the present study was analyzed the salivary activity, the dental mineralization and the role of matrix metalloproteinase-9 (MMP-9) on this mineralization, in pups (30 days) of spontaneously hypertensive rats (SHR) treated, or not treated, with atenolol. Female SHR and normotensive Wistar rats were treated during pregnancy and lactation periods with Atenolol 100mg/Kg/day by oral administration. For the control group, the animals received the same water volume without the drug. The salivary flow rate (stimulated by pilocarpine injection), the protein concentration (Lowry method), salivary amylase activity (kinetic method at 405 nm), the weight of salivary glands (parotid, submandibular and sublingual), the enamel and dentin microhardness of incisors and molars teeth and the matrix metalloproteinase-9 (MMP-9, gelatinase B) localization (imunoperoxidase) in dental tissue were compared between SHR and Wistar pups of female rats treated or not with atenolol. The results were analyzed by parametric (ANOVA or Student s tests) or non-parametric (Kruskal-Wallis) tests (p<0,05). The salivary flow rate and salivary protein concentration were reduced in SHR pups. There was no alteration in amylase activity between groups. The salivary glands weight was not different between SHR and Wistar pups either. Decreased enamel and dentin microhardness were observed in incisors and molar teeth of SHR pups. No alterations in MMP-9 positive staining were observed in predentin and odontoblasts of both groups, however the density of stained ameloblasts cells and external enamel surface were higher in incisors teeth of SHR pups. Atenolol-treated SHR and Wistar rats pups showed decrease in submandibular gland weight, in saliva s flow rate and protein concentration, but no alteration in amylase activity. Atenolol increased enamel and dentin microhardness of incisors teeth of SHR and...(Complete abstract, click electronic address below)
Books on the topic "Atenolol"
1
Nederfors, Tommy. Xerostomia: Prevalence and pharmacotherapy : with special reference to -adrenoceptor antagonists. [Göteborg Univ.], 1996.
Find full text
2
Parker, Philip M., and James N. Parker. Atenolol: A medical dictionary, bibliography, and annotated research guide to internet references. ICON Health Publications, 2003.
Find full text
3
Wieskamp, Felizitas Kleine. Durchblutung im partiell ischämischen Myokard unter Einfluss von Oxyfedrin nach Prämedikation mit Atenolol. [s.n.], 1985.
Find full text
4
Kaum, Heinz-Josef. Beeinflussung des Plasma-Katecholamin-Spiegels durch eine antihypertensive Therapie mit adrenergen Rezeptorenblockern: Vergleich des Alpha-Blockers Prazosin mit dem Beta-Blocker Atenolol bei Patienten mit essentieller Hypertonie unter Ruhe- und unter Belastungsbedingungen. [s.n.], 1987.
Find full text
6
Publications, ICON Health. Atenolol - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2003.
Find full text
7
Junge, Almut. Wirkung einer Einzeldosis der b-Blocker Metoprolol und Atenolol auf den elektrischen Hautwiderstand. 1995.
Find full text
8
Job, Steve. Atenolol: BEST Medication for Treating Chest Pain and to Improve Survival after a Heart Attack. Independently Published, 2019.
Find full text
9
Reichert-Jünger, Christine. Pharmakokinetik und Pharmakodynamik der [beta]-Adrenorezeptorenblocker Atenolol und Metoprolol in der perioperativen Phase bei aorto-coronarer Bypass-Operation. 1989.
Find full text
10
Jones, Doctor Vicki. Atenolol: Functions, Uses, Dosage, Side Effects and Precautions for the Active Medication Used to Treat High Blood Pressure. Independently Published, 2019.
Find full textBook chapters on the topic "Atenolol"
1
Peter, Helga, and Thomas Penzel. "Atenolol." In Springer Reference Medizin. Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_333-1.
Full text
2
Schneeweiss, Adam, and Gotthard Schettler. "Atenolol." In Developments in Cardiovascular Medicine. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-2063-0_37.
Full text
3
de Groot, Anton C. "Atenolol." In Monographs In Contact Allergy. CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-52.
Full text
4
Peter, Helga, and Thomas Penzel. "Atenolol." In Springer Reference Medizin. Springer Berlin Heidelberg, 2025. https://doi.org/10.1007/978-3-662-65186-5_333.
Full text
5
Spahn, H., W. Mühlberg, E. Mutschler, and D. Platt. "Age-Dependent Pharmacokinetics of Atenolol in Patients with Multiple Diseases." In Drugs and Aging. Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70788-9_15.
Full text
6
Dow, Lindsey, and M. Searle. "Transdermal Clonidine/Atenolol in the Management of Mild to Moderate Hypertension." In Low Dose Oral and Transdermal Therapy of Hypertension. Steinkopff, 1985. http://dx.doi.org/10.1007/978-3-642-53785-1_21.
Full text
7
Lijnen, P., J. R. M’Buyamba-Kabangu, B. Lepira, R. Fagard, and A. Amery. "Determinants of the Hypotensive Action of Nitrendipine and Atenolol in African Black Patients." In How Should Elderly Hypertensive Patients Be Treated? Springer Japan, 1989. http://dx.doi.org/10.1007/978-4-431-68340-7_14.
Full text
8
Brown, J. S., J. A. Tweed, and K. G. Edwards. "Efficacy and Tolerance of Isosorbide-5-Mononitrate with Atenolol in Chronic Stable Angina." In Mononitrate II. Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72689-7_32.
Full text
9
Azzam, Khaldun M. AL, and Hassan Y. Aboul-Enein. "Simultaneous Determination of Atenolol and Amiloride by Capillary Electrophoresis with Capacitively Coupled Contactless Conductivity Detection (C4D)." In Methods in Molecular Biology. Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-029-8_7.
Full text
10
Zhang, Jianhua, Jiahua Shi, Benedict Jia Hong Lee, et al. "Proteomic Analysis of Vascular Smooth Muscle Cells with S- and R-Enantiomers of Atenolol by iTRAQ and LC-MS/MS." In Methods in Molecular Biology. Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-405-0_4.
Full textConference papers on the topic "Atenolol"
1
Mamina, O., V. Kabachny, and O. Lozova. "THE DETERMINATION OF ATENOLOL BY HPLC METHOD." In THEORETICAL AND PRACTICAL ASPECTS OF MODERN SCIENTIFIC RESEARCH. European Scientific Platform, 2021. http://dx.doi.org/10.36074/logos-30.04.2021.v2.53.
Full text
2
Vidal, Nathália Lohamy da Silva, Bárbara Longhini Gonzalez, Dyessica Santos Pellogia, Heloisa Almeida Montes Silva, João Carlos Palazzo de Mello, and Daniela Cristina de Medeiros Araújo. "Controle de qualidade de comprimidos de atenolol genérico em relação ao medicamento referência." In II Congresso Internacional Interdisciplinar da Uningá. Editora Uningá, 2023. http://dx.doi.org/10.46311/ed.un.20221018137.
Full textAbstract:
O atenolol é um agente betabloqueador anti-hipertensivo e antianginoso utilizado principalmente no tratamento da hipertensão arterial, da angina pectoris e de arritmias cardíacas. Este trabalho teve como objetivo realizar o controle de qualidade físico-químico de comprimidos de atenolol, comparando o medicamento genérico à referência, a fim de avaliar a qualidade dos produtos e verificar se apresentam equivalência farmacêutica. Para isso, foram realizados os testes de peso médio, friabilidade, dissolução e desintegração. De acordo com os resultados dos testes, foi possível observar que as amostras testadas cumpriram os requisitos de qualidade conforme os parâmetros descritos na Farmacopeia Brasileira 6.ª edição.
3
Li, Zhengkai. "Comparison of Enalapril and Atenolol Hypertension Drugs’ Principle." In The International Conference on Biomedical Engineering and Bioinformatics. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0011218500003443.
Full text
4
Al-Samarrai, Shorouk Hatim, and Eman Thiab Al-Samarrai. "Assay of atenolol in Novaten tablets by visible spectrophotometer." In 1ST SAMARRA INTERNATIONAL CONFERENCE FOR PURE AND APPLIED SCIENCES (SICPS2021): SICPS2021. AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0122916.
Full text
5
Yang, Mingxuan. "Cross Examination of Atenolol and Canderstan Cilexetil on the Treatment of Hypertension." In The International Conference on Biomedical Engineering and Bioinformatics. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0011381300003443.
Full text
6
KIM, HYUNGSEOP, JUNGHO HEO, DONGHEON YANG, et al. "RESPONSES TO HEAD-UP TILT TEST IN VASOVAGAL SYNCOPE AFTER ATENOLOL TREATMENT." In Proceedings of the 31st International Congress on Electrocardiology. WORLD SCIENTIFIC, 2005. http://dx.doi.org/10.1142/9789812702234_0193.
Full text
7
Saleem, Basima A. A., Afyaa M. Yonus, and Najih H. Shekho. "Visible spectrophotometric method for quantitative estimation of atenolol drug using cerium (III and IV)." In 3RD INTERNATIONAL CONFERENCE ON ENERGY AND POWER, ICEP2021. AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0107688.
Full text
8
Jassim, Baidaa Adnan, and Ali Ibraheem Khaleel. "Determination of atenolol in bulk and pharmaceutical normotic by derivative spectroscopy method for ion-pair complex." In 1ST SAMARRA INTERNATIONAL CONFERENCE FOR PURE AND APPLIED SCIENCES (SICPS2021): SICPS2021. AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0121893.
Full text
9
Lombard, A., J. Vigneron, E. D’huart, and B. Demore. "3PC-070 Evaluation of compatibility of acetylsalicylic acid and atenolol with medications commonly used in intensive care units." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.45.
Full text
10
Alwan, Dhilal Sukban, Mohammad Salim Abdulaziz, and Ahmed Mahdi Saeed. "Reversed-phase liquid chromatography to estimate the effectiveness of amlodipine besylate, atenolol, and aspirin in certain pharmaceutical tablets." In International Conference of Chemistry and Petrochemical Techniques (ICCPT). AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0094011.
Full text